genistein-8-c-glucoside and Diabetes-Mellitus--Type-2

genistein-8-c-glucoside has been researched along with Diabetes-Mellitus--Type-2* in 1 studies

Other Studies

1 other study(ies) available for genistein-8-c-glucoside and Diabetes-Mellitus--Type-2

Article	Year
Glucosylpolyphenols as Inhibitors of Aβ-Induced Fyn Kinase Activation and Tau Phosphorylation: Synthesis, Membrane Permeability, and Exploratory Target Assessment within the Scope of Type 2 Diabetes and Alzheimer's Disease. Journal of medicinal chemistry, 2020, 10-22, Volume: 63, Issue:20 Despite the rapidly increasing number of patients suffering from type 2 diabetes, Alzheimer's disease, and diabetes-induced dementia, there are no disease-modifying therapies that are able to prevent or block disease progress. In this work, we investigate the potential of nature-inspired glucosylpolyphenols against relevant targets, including islet amyloid polypeptide, glucosidases, and cholinesterases. Moreover, with the premise of Fyn kinase as a paradigm-shifting target in Alzheimer's drug discovery, we explore glucosylpolyphenols as blockers of Aβ-induced Fyn kinase activation while looking into downstream effects leading to Tau hyperphosphorylation. Several compounds inhibit Aβ-induced Fyn kinase activation and decrease pTau levels at 10 μM concentration, particularly the per- Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Membrane Permeability; Cholinesterases; Diabetes Mellitus, Type 2; Drug Discovery; Glucosides; Glycoside Hydrolases; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Molecular Structure; Phosphorylation; Polyphenols; Proto-Oncogene Proteins c-fyn; tau Proteins	2020

Article

Year

Glucosylpolyphenols as Inhibitors of Aβ-Induced Fyn Kinase Activation and Tau Phosphorylation: Synthesis, Membrane Permeability, and Exploratory Target Assessment within the Scope of Type 2 Diabetes and Alzheimer's Disease.

Journal of medicinal chemistry, 2020, 10-22, Volume: 63, Issue:20

Despite the rapidly increasing number of patients suffering from type 2 diabetes, Alzheimer's disease, and diabetes-induced dementia, there are no disease-modifying therapies that are able to prevent or block disease progress. In this work, we investigate the potential of nature-inspired glucosylpolyphenols against relevant targets, including islet amyloid polypeptide, glucosidases, and cholinesterases. Moreover, with the premise of Fyn kinase as a paradigm-shifting target in Alzheimer's drug discovery, we explore glucosylpolyphenols as blockers of Aβ-induced Fyn kinase activation while looking into downstream effects leading to Tau hyperphosphorylation. Several compounds inhibit Aβ-induced Fyn kinase activation and decrease pTau levels at 10 μM concentration, particularly the per-

Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Membrane Permeability; Cholinesterases; Diabetes Mellitus, Type 2; Drug Discovery; Glucosides; Glycoside Hydrolases; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Molecular Structure; Phosphorylation; Polyphenols; Proto-Oncogene Proteins c-fyn; tau Proteins

2020